Kornimate/medical-research-clean huggingface dataset:
a feasibility trial of ocm supplements for the treatment of nafld

Conditions: NAFLD

Summary: the purpose of the study is to assess the feasibility of a trial to test the effects of homocysteine (hcy) lowering supplements in patients with nafld. nafld patients will be asked to take hcy lowering supplements (vitamin b12, folate, vitamin b6, and betaine) daily for 12 weeks. over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits to complete activities such as physical exam, fibroscan, blood draws, and questionnaires.

the purpose of the study is to assess the feasibility of a trial to test the effects of homocysteine (hcy) lowering supplements in patients with nafld. nafld patients will be asked to take hcy lowering supplements (vitamin b12, folate, vitamin b6, and betaine) daily for 12 weeks. over the course of approximately 12 to 13 weeks, participants will complete two in person visits and two phone visits. during the in person visits nafld participants will complete the following activities: * review medical history * physical examination * vital signs (blood pressure, heart rate, respiratory rate, body temperature) * measure height, weight, body mass index, and waist circumference * grip test * fasting blood tests * pregnancy test (if applicable) * fibroscan with cap score * qol questionnaire

Eligibility criteria:
we will enroll nafld patients, blocked by age 50 years (≤ 50; \> 50) and sex (m; f, four patients/subjects in each block). inclusion criteria for nafld group: 1. increased hepatic fat accumulation diagnosed by either abdominal ultrasound or ct and elevated cap score of 280 db/m or higher 2. homa-ir ≥ 2 or the diagnosis of metabolic syndrome 3. chronic elevation of transaminases: alt elevation (more than 2 times during the past 12 months, defined by 19 u/l for women and 30 u/l for men 31) 4. stable use of any potential anti-nash therapy (i.e., vitamin e, pioglitazone, glucagon like peptide 1 agonist, etc.) for 6 months prior to screening. 5. aged 18+ years 6. able to provide legal consent exclusion criteria for nafld group: 1. any contraindication to the study supplements 2. inability to obtain valid fibroscan measures at the screening 3. pregnancy or lactation 4. clinical diagnosis of cirrhosis or other chronic liver diseases 5. recent use of steatogenic medications 6. excess alcohol use (\>21/ \>14 drinks weekly in men/women) 7. chronic kidney disease 8. supplement use within 30 days, containing any of the study supplements 9. total parenteral nutrition 10. any clinical conditions associated with malabsorption 11. any active diagnosis of malignancy 12. use of immunosuppression
fenofibrate in combination with ursodeoxycholic acid in primary biliary cholangitis

Conditions: Primary Biliary Cholangitis

Summary: the main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (pbc)


Eligibility criteria:
inclusion criteria: * must have provided written informed consent * age 18-75 years; * bmi 17-28 kg/m2 * male or female with a diagnosis of pbc, by at least two of the following criteria: 1. history of alkaline phosphatase（alp） above upper limit of normal（uln） for at least six months; 2. positive anti-mitochondrial antibody (ama) titers (\>1/40 on immunofluorescence or m2 positive by enzyme linked immunosorbent assay (elisa) or positive pbc-specific antinuclear antibodies; 3. documented liver biopsy result consistent with pbc. * incomplete response to udca defined by 1 x uln\< alp \<= 1.67 x uln * taking udca for at least 6 months (stable dose for ≥ 3 months) prior to day 0 exclusion criteria: * history or presence of other concomitant liver diseases. * alt or ast \> 5×uln, total bilirubin（tbil） \> 3×uln. * if female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating. * allergic to fenofibrate or ursodeoxycholic acid. * taking hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months, and long-term hormonal users. recurrent variceal bleeding, poorly controlled hepatic encephalopathy or refractory ascites. * patients with a history of severe cardiac, cerebrovascular, renal, respiratory disease or functional failure, and psychiatric disorders (including those due to alcohol and drug abuse). * creatinine \>1.5×uln and creatinine clearance \<60 ml/min. * currently using statins (such as pravastatin, fluvastatin, and simvastatin), other fibrates (such as gemfibrozil and bezafibrate), and drugs structurally similar to fenofibrate (like ketoprofen). * planned to receive an organ transplant or an organ transplant recipient. * needing liver transplantation within 1 year according to the mayo rick score. * any other condition(s) that would compromise the safety of the subject or compromise
a prospective, split-face, randomized study of the poly-d, l lactic acid (pdlla) for photoaged skin

Conditions: Pigmentation; Pigmentation Disorder

Summary: juvelook® (vaim, korea) is made by dissolving irregular pdlla particles in a solvent mixture of dmso (dimethylsulfoxide) and ec (ethylene carbonate) and then injecting them through microneedling to create reticulated foamy microspheres, which are hollow spherical particles. it received ce approval in europe in 2020 and is widely used domestically as a material for tissue restoration, including skin fillers and collagen stimulators. the spherical shape with internal foam structure of pdlla exhibits excellent biocompatibility, biodegradability, porosity, and mechanical strength. it allows for the control of particle size and acts as a collagen stimulator while gradually dissolving over time. this stimulates fibroblast cells and promotes skin rejuvenation. in clinical practice, juvelook® particles are injected to address various concerns such as facial wrinkles, increased elasticity, depressed scars, acne scars, accident scars, under-eye hollows, freckles, whitening effects, and neck wrinkles. therefore, this study aims to investigate the efficacy of juvelook® not only in volume augmentation but also in improving photoaged skin.


Eligibility criteria:
inclusion criteria: 1. healthy adult women over 30 years old with photoaged skin. 2. individuals who have a clear understanding of the purpose and content of the study, as well as the potential risks and side effects, and voluntarily sign the informed consent form to participate in the clinical trial. 3. individuals who are physically healthy and can be tracked and observed throughout the entire study period. exclusion criteria: 1. individuals who have received anti-aging/whitening treatments (such as laser or chemical peels) on their face within 3 months prior to the start of the study. 2. individuals who have applied anti-aging/whitening agents to their face within 3 months prior to the start of the study. 3. pregnant or breastfeeding women. 4. individuals who are participating in other clinical trials. 5. individuals who, in the judgment of the researchers, are deemed ineligible to participate in the study.
randomized comparison of endocardial versus epicardial - from the coronary sinus - left ventricular pacing for resynchronization in heart failure.

Conditions: Heart Failure; Cardiomyopathy, Dilated; Coronary Disease

Summary: biventricular pacing is a validated treatment for patients suffering from heart failure resistant to medical treatment. however, up to 30% of the patients are non responsive to this strategy using the coronary sinus approach to pace the left ventricle (lv). it has been demonstrated that the magnitude of the improvement was highly dependant on the lv pacing site. the coronary sinus approach rarely offers more than 1 or 2 potential pacing sites. resynchronisation using a transeptal approach to pace the left ventricle on the cardiology has been shown feasible on small series. we therefore would like to compare these two approached in a randomised prospective study to confirm the hypotheses that endocardial lv pacing by offering multiple choices for the pacing sites reduces the number of non responders and is associated with greater hemodynamic benefit when compared to the conventional coronary sinus approach.


Eligibility criteria:
inclusion criteria: * adult (aged 18 or above) * cardiac insufficiency of whatever cause (ischemic or non-ischemic) * left ventricular ejection fraction \<35% * nyha class iii or iv with optimal medical treatment * qrs duration \> 120 ms * sinus rhythm * patient must have signed informed consent * patient must be registered in the national health care system exclusion criteria: * aged under 18 * patient with a mitral or aortic prosthesis * patient with contraindication to anti-coagulants * pregnant women * participation in another study * patient with contraindication for left ventricle catheterization by retrograde aortic approach , as a severe aortic stenosis requiring surgery, or an ascending aorta aneurism

Keywords: heart failure cardiomyopathy, dilated coronary disease cardiac pacing, artificial cardiac resynchronization therapy hemodynamics randomized controlled trials open study
validation of a predictive model to estimate the risk of conversion to clinically significant macular edema and/or vision loss in mild nonproliferative diabetic retinopathy in diabetes type 2

Conditions: Diabetic Retinopathy

Summary: this project aims to validate a predictive model of diabetic retinopathy progression to clinically significant macular edema (csme) needing photocoagulation and/or vision loss. the coimbra predictive model (cpm), based on retinal thickness, microaneurysms number, hba1c and ldl levels, established on a set of 52 diabetic patients, will be tested on a population of 400 patients/eyes to be enrolled into the study. these patients will perform 2 visits at 6-month interval (v0 and v6) to classify each patient into one of the 3 previously established phenotypes. two years after (v24) patients will be reexamined. the occurrence of end-points, achieved by the patients, are expected to validate our predictive model.


Eligibility criteria:
inclusion criteria: * diabetes type 2 according to 1985 who criteria. * age between 35 and 75 years. * mild non-prolipherative retinopathy (based on etdrs criteria) * best corrected visual acuity \>20 /25 * refraction with a spherical equivalent less than 5 dp. * inform consent exclusion criteria: * cataract or other eye disease that may interfere with fundus examinations * glaucoma * vitreous syneresis or posterior vitreous detachment * other retinal vascular disease * recent intraocular surgery * previous laser therapy * dilatation of the pupil \< 5 mm
effect of 3 years of exercise on development of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this is a substudy of "generation 100". in that study, 4000 healthy persons between 70 and 75 will be randomised to a moderate intensity training group, a high intensity training group or control group, with 3 years of exercise. the investigators will follow these persons and register all who develop atrial fibrillation during these 3 years, and at follow-up after ended intervention to see if there is differences in the number of persons who develop atrial fibrillation in the 3 groups.


Eligibility criteria:
inclusion criteria: * participating in the "generation 100" study exclusion criteria: -

Keywords: atrial fibrillation prevention exercise
mesenchymal stem cell treatment for primary osteoarthritis knee

Conditions: Osteoarthritis Knee

Summary: the purpose of this study is to evaluate the safety and preliminary efficacy of autologous adipose-derived mesenchymal stem cells (admscs) treatment for patients with primary osteoarthritis knee. three intra-articular injections of autologous admscs will be performed to subjects at a weekly interval.


Eligibility criteria:
inclusion criteria: 1. subject has bilateral kellgren and lawrence grade ii-iii primary osteoarthritis as determined by x-ray. 2. subject's pain score is 8-13 points (lequesne's index). 3. ages between 50-70 years. 4. signed informed consent from the subject. 5. female subjects should be post-menopausal women exclusion criteria: 1. subject infected with hepatitis b, hepatitis c, hiv, syphilis or htlv. 2. subject not suitable for liposuction surgery. 3. subject with hypersensitivity/allergy to anesthetic. 4. subject's creatinine values higher than 1.6mg/dl. 5. subject with body mass index, bmi over 30. 6. subject's studied knee treated with intra-articular injection therapy within 6 months prior to screen. 7. subject has undergone surgery on either side of knee, including fracture surgery, arthroscopic surgery, meniscus repair surgery, or cruciate ligament reconstruction surgery. 8. subject enrolled in any other cell therapy studies within the past 30 days. 9. subject who the investigator considers inappropriate for the clinical trial due to any other reasons than those listed above. 10. subject has a history of gouty arthritis, septic arthritis, rheumatoid arthritis and any other autoimmune arthritis of the knee joint. 11. subject has had major medical problems in vital organs, such as; heart, liver, kidney, or lung.
pre-operative carbohydrate drink to preserve peri-operative insulin sensitivity

Conditions: Laparoscopic Abdominal Surgery

Summary: enhanced recovery after surgery (eras) pathways include multiple evidence-based interventions delivered throughout the peri-operative period that aim to attenuate the surgical stress response and support rapid physiologic and functional recovery.a key element of the eras pathway is the administration of a clear carbohydrate-rich beverage 2-3 h before surgery in order to keep the patient in a fed state rather than a fasted state when they go to the operating room. the aim of the current study is to investigate the impact of a drink containing simple carbohydrate on attenuating surgical stress induced insulin resistance in patients undergoing major laparoscopic abdominal surgery, compared to drinks containing maltodextrin.


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. planned laparoscopic partial colon resection for non-metastatic neoplastic or benign disease (including right, transverse, left or sigmoid)) 3. hba1c less than or equal to 5.7% 4. not receiving any kind of glucose lowering medication. exclusion criteria: 1. are already diagnosed with diabetes or pre diabetes (hba1c \> 5.7%) 2. are pre-diabetic receiving glucose lowering intervention (any glucose lowering medication) 3. have renal or liver dysfunction (serum creatinine above 1.4 mg/dl in women and 1.5 mg/dl in men, bilirubin \>2.9 mg/dl) 4. will undergo extended resection of adjacent organs 5. non-elective operations 6. new stoma created 7. have conditions precluding participation in the eras pathway (e.g. dementia, disabling orthopedic and neuromuscular disease, psychosis) 8. have conditions requiring preoperative fasting: documented gastroparesis, patient on metoclopramide and/or domperidone, achalasia, dysphagia (any difficulty with swallowing), or fluid restriction (e.g. dialysis, pulmonary oedema, congestive heart failure). 9. have cardiac abnormalities, severe end-organ disease such as cardiac failure (new york heart association classes iii-iv), chronic obstructive pulmonary disease (documented by abnormal pulmonary function test), morbid obesity (bmi \>40 kg/m2), anemia (hematocrit \< 30 %, hemoglobin \<100g/l, albumin \< 25mg/dl) 10. have received steroids for longer than 30 days 11. have poor english or french comprehension.

Keywords: carbohydrate drink post operative complication insulin resistance fasting blood glucose
copenhagen obesity risk assessment study

Conditions: Metabolic Syndrome; Abdominal Obesity; Heart Disease; Type 2 Diabetes

Summary: the aim of the present study is to assess the effect of a high intake of industrially produced trans fatty acids for 16 weeks on abdominal obesity and risk markers of type 2 diabetes and heart disease in healthy, moderately overweight, postmenopausal women.


Eligibility criteria:
inclusion criteria: * age 45-70 years * bmi 25-32 * waist circumference \> 80 cm * postmenopausal for at least 1 year exclusion criteria: * bp \> 160/100 mmhg * fasted blood glucose \> 7 mm * fasted ldl-cholesterol \> 6 mm * fasted triglycerides \> 3 mm * diabetes mellitus or other chronic diseases * current or previous cardiovascular disease * weight change \> 3 kg within last 2 months * use of anti-hypertensive drugs * use of statins/fibrates * use of fish oil supplements * smoking * hard physical activity \> 10 h/week

Keywords: trans fat obesity insulin sensitivity
cemented vs cementless in bilateral tka

Conditions: Osteoarthritis; Total Knee Arthroplasty

Summary: to compare the functional outcomes between cemented and cementless tka in bilateral knee replacement patient.

to compare early functional outcomes, radiographic finding and operative time between cemented and cementless modern implant in sequential bilateral total kee arthroplasty.

Eligibility criteria:
inclusion criteria: * asa status 1 or 2 * diagnosed with bilateral osteoarthritis of the knees * participant understand and consent to the protocol of the trial exclusion criteria: * morbid obesity (bmi \>40) * inflammatory arthritis * osteoporosis * metabolic bone disease * bone defect that seen from radiographs

Keywords: cemented cementless total knee arthroplasty short term outcome functional outcome
motor and neurophysiological changes after ischemic conditioning in individuals with stroke

Conditions: Stroke

Summary: the goal of this clinical trial is to test ischemic conditioning (blood flow restriction) as a neuromodulatory technique to improve gait function in stroke. neuromodulation is emerging as a promising adjunct strategy to facilitate changes in brain activity and improve motor behavior following a neurological injury such as stroke. the main questions this trial aims to answer are: * can ischemic conditioning produce neuromodulatory changes in the lower limb primary motor cortex? * can ischemic conditioning be used as a neuromodulatory technique to improve strength, motor control, and gait speed in individuals with stroke when compared to sham ischemic conditioning? participants will take part in two sessions of ischemic conditioning where a cuff (similar to ones that measure blood pressure) will be placed around the thigh and inflated to one of two blood flow restriction pressures (real or sham). each participant will experience measures of brain activity and motor behavior testing before and after both sessions (ischemic conditioning and sham ischemic conditioning). researchers will investigate ischemic conditioning as neuromodulation modality in stroke to see if ischemic conditioning can produce beneficial changes in brain activity and improvements on subsequent motor behavior tasks.


Eligibility criteria:
inclusion criteria: * single, stroke \> 6 months since onset * residual hemiparetic gait deficits (e.g., abnormal gait pattern) exclusion criteria: * lesions affecting the brainstem or cerebellum * other neurological disorders that may interfere with motor function * unhealed decubiti, persistent infections that may interfere with ability to perform test procedures * significant cognitive or communication impairment (mini-mental state examination (mmse\<21)), which could impede the understanding of the purpose of procedures of the study * botulinum toxin (botox) treatments to the lower limb within the past 6 months * pregnant women * contraindications to transcranial magnetic stimulation (tms) or ischemic conditioning (ic) (listed below) tms general exclusion criteria: * previous adverse reaction to tms * skull abnormalities or fractures * concussion within the last 6 months * unexplained, recurring headaches * implanted cardiac pacemaker * metal implants in the head or face * history of seizures or epilepsy * use of medications that could alter cortical excitability or increase risk of seizure (e.g., antidepressants, antipsychotics, anxiolytics, anticonvulsants) * current pregnancy ic general exclusion criteria: * history of thrombosis (i.e., blood clots) including venous thrombosis or deep vein thrombosis (dvt). * blood clots in the leg, or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., open wounds in the leg, bruising, nerve damage, etc.) * peripheral arterial grafts in the lower extremity * history of uncontrolled hypertension * history of peripheral vascular disease or hematological disease
effects of music on acute postoperative pain intensity and mobility after fragility hip fracture

Conditions: Hip Fractures

Summary: music has been proven to be beneficial in postoperative care by reducing pain. the effects of music listening to reduce pain postoperatively are well studied among cases undergoing elective orthopaedic surgery. no study has been conducted focusing on pain control among cases with fragility hip fractures in an acute ward setting with non-schedule non-elective orthopaedic operation. in queen elizabeth hospital a standardized analgesic protocol is used for all fragility hip fracture cases unless contraindicated, a suboptimal post-operative pain control is not uncommonly seen. stepping up analgesics is usually a concern in the elderly with a higher rate of side effects, a safe and simple non-pharmacological intervention for pain control is therefore needed. the aim of this study is to study the effectiveness of incorporating music on pain intensity and mobility with the standard postoperative rehabilitation care of fragility hip fracture in queen elizabeth hospital.


Eligibility criteria:
inclusion criteria: 1. emergency admitted to qeh/g9 due to fragility hip fracture (#nof or # tof) within the study period 2. plan for surgical intervention 3. able to provide written informed consent 4. able to communicate in cantonese/ putonghua/ english exclusion criteria: 1. history of dementia 2. acute delirium upon admission 3. disorientated to time, person or place 4. concurrent fracture at other sites 5. utilization of other analgesics on top of pain protocol 6. appreciable deficits in hearing or vision 7. hemodynamically unstable 8. plan for neurolysis/ nerve block as definite treatment or opt for conservative treatment

Keywords: pain control music fragility hip fracture